Last reviewed · How we verify
ROTAVIN (liquid formulation)
ROTAVIN is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus infection.
ROTAVIN is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus infection. Used for Prevention of rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | ROTAVIN (liquid formulation) |
|---|---|
| Sponsor | Center for Research and Production of Vaccines and Biologicals, Vietnam |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened rotavirus strains that replicate in the intestinal tract, triggering both humoral (antibody) and cell-mediated immune responses without causing severe disease. This primes the immune system to recognize and neutralize wild-type rotavirus upon natural exposure, preventing or reducing the severity of rotavirus gastroenteritis.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and young children
Common side effects
- Diarrhea
- Vomiting
- Fever
- Irritability
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: